These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31691114)

  • 1. External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer.
    Brinkmann S; Noordman BJ; Hölscher AH; Biermann K; van Klaveren D; Bollschweiler E; Pütz K; van Lanschot JJB; Drebber U
    Ann Surg Oncol; 2020 Apr; 27(4):1250-1258. PubMed ID: 31691114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Pretreatment Pathological Tumor Extent in Patients Treated With Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal or Junctional Cancer.
    Shapiro J; Biermann K; van Klaveren D; Offerhaus GJ; Ten Kate FJ; Meijer SL; van Berge Henegouwen MI; Steyerberg EW; Wijnhoven BP; Lanschot JJ
    Ann Surg; 2017 Feb; 265(2):356-362. PubMed ID: 28059964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Optimal Parameters for Assessing Lymph Node Status of Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
    Huang X; Jiang D; Jian Z; Zeng Z; Zhang S; Fan H; Sun T; Tang H; Hou Y; Tan L
    Ann Surg Oncol; 2024 Feb; 31(2):883-891. PubMed ID: 38038788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
    Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
    Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
    Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
    Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC
    Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliability of clinical nodal status regarding response to neoadjuvant chemoradiotherapy compared with surgery alone and prognosis in esophageal cancer patients.
    Dijksterhuis WPM; Hulshoff JB; van Dullemen HM; Kats-Ugurlu G; Burgerhof JGM; Korteweg T; Mul VEM; Hospers GAP; Plukker JTM
    Acta Oncol; 2019 Nov; 58(11):1640-1647. PubMed ID: 31397195
    [No Abstract]   [Full Text] [Related]  

  • 8. ypN0: Does It Matter How You Get There? Nodal Downstaging in Esophageal Cancer.
    Zanoni A; Verlato G; Giacopuzzi S; Motton M; Casella F; Weindelmayer J; Ambrosi E; Di Leo A; Vassiliadis A; Ricci F; Rice TW; de Manzoni G
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):998-1004. PubMed ID: 27480358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
    Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
    Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Tumor Staging System Incorporating Tumor Regression Grade (TRG) With Lymph Node Status (ypN-Category) Results in Better Prognostication Than ypTNM Stage Groups After Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.
    Wong IYH; Chung JCY; Zhang RQ; Gao X; Lam KO; Kwong DLW; Chao YK; Law SYK
    Ann Surg; 2022 Nov; 276(5):784-791. PubMed ID: 35876374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of survival in patients with oesophageal or junctional cancer receiving neoadjuvant chemoradiotherapy and surgery.
    Shapiro J; van Klaveren D; Lagarde SM; Toxopeus EL; van der Gaast A; Hulshof MC; Wijnhoven BP; van Berge Henegouwen MI; Steyerberg EW; van Lanschot JJ
    Br J Surg; 2016 Jul; 103(8):1039-47. PubMed ID: 27115731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma.
    Hölscher AH; Drebber U; Schmidt H; Bollschweiler E
    Ann Surg; 2014 Nov; 260(5):779-84; discussion 784-5. PubMed ID: 25379849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Relevance of Lymph Node Regression After Neoadjuvant Chemoradiation for Esophageal Cancer.
    Philippron A; Bollschweiler E; Kunikata A; Plum P; Schmidt C; Favi F; Drebber U; Hölscher AH
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):549-558. PubMed ID: 28043475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
    Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
    J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of Lymph Node Response After Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Depypere L; De Hertogh G; Moons J; Provoost AL; Lerut T; Sagaert X; Coosemans W; Van Veer H; Nafteux P
    Ann Thorac Surg; 2021 Dec; 112(6):1847-1854. PubMed ID: 33352178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.
    Tong DK; Law S; Kwong DL; Chan KW; Lam AK; Wong KH
    Ann Surg Oncol; 2010 Aug; 17(8):2184-92. PubMed ID: 20217248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma.
    Mitchell KG; Ikoma N; Nelson DB; Maru DM; Erasmus JJ; Weston BR; Vaporciyan AA; Antonoff MB; Mehran RJ; Rice DC; Roth JA; Swisher SG; Sepesi B; Walsh GL; Correa AM; Das P; Blum MA; Badgwell BD; Hofstetter WL
    Ann Thorac Surg; 2019 Sep; 108(3):845-851. PubMed ID: 31102632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Pretreatment PET/CT Nodal Status on Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiation.
    Chen JX; Lu TY; Fang HY; Lin YS; Lee JM
    World J Surg; 2020 Jul; 44(7):2323-2331. PubMed ID: 32296872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.